Editas Medicine, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 153.22 million compared to USD 220.43 million a year ago. Basic loss per share from continuing operations was USD 2.02 compared to USD 3.21 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.395 USD | +3.75% | +1.69% | -46.59% |
May. 30 | Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating | MT |
May. 14 | Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.59% | 428M | |
+46.13% | 54.63B | |
-6.62% | 39.92B | |
+37.07% | 38.82B | |
+13.27% | 26.86B | |
-11.17% | 26.22B | |
-21.64% | 18.78B | |
+25.56% | 12.21B | |
+0.40% | 12.16B | |
+25.74% | 11.94B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023